CCP 08

Drug Profile

CCP 08

Alternative Names: CCP-08

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Tris Pharma
  • Class Antitussives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Common cold; Cough

Most Recent Events

  • 14 Dec 2017 Vernalis announces intention to re-submit the NDA for CCP 08 in Cough and Common cold in USA in 2018
  • 07 Aug 2017 Vernalis receives complete response letter from the FDA for CCP 08 in Cough and Cold
  • 21 Dec 2016 FDA assigns PDUFA action date of 04/08/2017 for CCP 08 for Cold
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top